Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 1
2001 1
2002 2
2006 2
2007 1
2008 2
2011 4
2012 2
2013 6
2014 3
2015 2
2016 4
2017 3
2018 5
2019 3
2020 2
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Results by year
Filters applied: . Clear all
Page 1
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Peyrade F, et al. Among authors: fitoussi o. Lancet Oncol. 2011 May;12(5):460-8. doi: 10.1016/S1470-2045(11)70069-9. Epub 2011 Apr 7. Lancet Oncol. 2011. PMID: 21482186 Clinical Trial.
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, Costello R, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, Coiffier B. Thieblemont C, et al. Among authors: fitoussi o. Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. Epub 2019 Nov 8. Br J Haematol. 2020. PMID: 31702836 Free PMC article. Clinical Trial.
High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Vercellino L, Cottereau AS, Casasnovas O, Tilly H, Feugier P, Chartier L, Fruchart C, Roulin L, Oberic L, Pica GM, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban C, López-Guillermo A, Sanhes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Briere J, Salles G, Gaulard P, Meignan M, Thieblemont C. Vercellino L, et al. Among authors: fitoussi o. Blood. 2020 Apr 16;135(16):1396-1405. doi: 10.1182/blood.2019003526. Blood. 2020. PMID: 31978225 Free PMC article. Clinical Trial.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G. Bachy E, et al. Among authors: fitoussi o. Blood. 2018 Jul 5;132(1):49-58. doi: 10.1182/blood-2017-11-816405. Epub 2018 Apr 17. Blood. 2018. PMID: 29666118 Free PMC article. Clinical Trial.
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR. Maurer MJ, et al. Among authors: fitoussi o. J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18. J Clin Oncol. 2014. PMID: 24550425 Free PMC article. Clinical Trial.
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T; Intergroupe Francophone du Myelome Multiple (IFM), Leleu X. Bobin A, et al. Among authors: fitoussi o. Leukemia. 2021 Oct 14. doi: 10.1038/s41375-021-01415-x. Online ahead of print. Leukemia. 2021. PMID: 34650225 No abstract available.
Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.
Feugier P, Brice P, Maynadié M, Franchi-Rezgui P, Hacini M, Laurent G, Suc E, Fitoussi O, Solal-Celigny P, Damaj G, Haioun C, Leconte P, Lazreg F, Boissard F, Pau D, Salles G. Feugier P, et al. Among authors: fitoussi o. Leuk Lymphoma. 2018 Oct;59(10):2485-2488. doi: 10.1080/10428194.2018.1434878. Epub 2018 Feb 28. Leuk Lymphoma. 2018. PMID: 29486625 No abstract available.
Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.
Chaoui D, Hacini M, Fitoussi O, Karlin L, Arkam Y, Jourdan E, Orfeuvre H, Voillat L, Sanhes L, Leprêtre S, Liu KL, Barry M, Tempescul A, Dilhuydy MS, Chaib A, Slama B, Labourey JL, Benbrahim O, Dreyfus B, Mahé B, Maynadié M, Delmer A, Benkanoun C, Boissard F, Gandon S, Veerabudun K, Choquet S; PERLE investigators. Chaoui D, et al. Among authors: fitoussi o. Leuk Lymphoma. 2019 Jun;60(6):1563-1567. doi: 10.1080/10428194.2018.1533130. Epub 2019 Jan 9. Leuk Lymphoma. 2019. PMID: 30624147 No abstract available.
Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.
Grelaud A, Fourrier-Réglat A, Fitoussi O, Facon T, Jové J, Bénichou J, Robinson P, Marit G, Rouyer M, Moore N, Noize P; VESUVE Study Group. Grelaud A, et al. Among authors: fitoussi o. Leuk Lymphoma. 2016;57(6):1349-54. doi: 10.3109/10428194.2015.1096354. Epub 2015 Nov 16. Leuk Lymphoma. 2016. PMID: 26397802
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Roussel M, Jaccard A, Pétillon MO, Belhadj-Merzoug K, Lepeu G, Chrétien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Attal M, Moreau P, Avet-Loiseau H, Hulin C, Facon T. Leleu X, et al. Among authors: fitoussi o. Clin Cancer Res. 2019 Jul 15;25(14):4224-4230. doi: 10.1158/1078-0432.CCR-18-3642. Epub 2019 May 3. Clin Cancer Res. 2019. PMID: 31053600 Free article. Clinical Trial.
40 results